Recovery research fieldbook Evidence, not treatment advice
Recovery archive

Published recovery field note

BPC-157 and Tamoxifen Interaction: Avoid | Peptide Database

Can you take BPC-157 with Tamoxifen? Avoid interaction (70% confidence). See pharmacological analysis, organ load, safety flags, and dosing guidance.

Context first

Study findings do not automatically establish clinical benefit, safety, dosing, or suitability for an individual.

Compound Profiles

BPC-157

Body Protection Compound-157 | Pentadecapeptide

Promotes blood vessel formation (angiogenesis), enhances collagen synthesis, modulates growth factor expression including VEGF, and protects against tissue damage through localized or systemic delivery pathways..

Tamoxifen

Selective Estrogen Receptor Modulator | PCT & Breast Cancer Treatment

Tamoxifen competitively binds to estrogen receptors (primarily ERalpha) and exerts tissue-selective effects depending on the local coactivator and corepressor environment. In breast tissue and the hypothalamus, tamoxifen acts as an estrogen antagonist, blocking estradiol-mediated signaling.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take BPC-157 with Tamoxifen?

Combining BPC-157 with Tamoxifen is not recommended. Both BPC-157 and Tamoxifen have anticoagulant or blood-thinning effects. Combined use significantly increases bleeding risk. Avoid unless under direct medical supervision.

Is BPC-157 and Tamoxifen safe together?

This combination carries significant risk. Both BPC-157 and Tamoxifen have anticoagulant or blood-thinning effects. Combined use significantly increases bleeding risk. Avoid unless under direct medical supervision. Consult a healthcare professional before combining.

What are the interactions between BPC-157 and Tamoxifen?

Both BPC-157 and Tamoxifen have anticoagulant or blood-thinning effects. Combined use significantly increases bleeding risk. Avoid unless under direct medical supervision. This assessment has 70% confidence and is inferred from pharmacological mechanism analysis.

How should I time BPC-157 and Tamoxifen?

BPC-157 has a half-life of <30 minutes and Tamoxifen has a half-life of ~5-7 days. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected topics

Follow this recovery question